AKT1 and renal cell carcinoma: In conclusion, the coexpression of caveolin-1 and activated components of the AKT/mTOR pathway represents a ‘linked molecular signature’ that identifies patients with localised RCC that are at high risk of developing metastatic disease that warrants greater postoperative surveillance.